Imetelstat and HIF inhibitors evolving use in MDS
Valeria Santini University of Florence, Florence, Italy
https://www.vjhemonc.com/event/iwmds-2022/
At Minute 8:08 Dr Santini states that she's had patients on Imetelstat for years - very positive video.
Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 69
- Joined: Sat Mar 19, 2016 3:48 pm
-
- Posts: 1665
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
mistergern, thank you for posting this. Dr. Santini clearly has a lot of experience with Imetelstat. One interesting small note is that we know the last patient was enrolled on Oct 1st 2021. The study technically ends one year after the last patient was enrolled. This means to me the blinding process ends then, I could be wrong about that. Much of the data has already been collected. Geron has guided results mid January but I do wonder if a late breaking submission for the Dec ASH meeting(finally) could be possible if data analysis allows. I don’t know if that would be possible but could certainly make a splash if so. bp
Re: Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
Any one take note of the sponsors........??
Platinum: Gilead & Novartis
Gold: Bristol Meyers Squibb
Silver: Syros
Bronze: Geron & Kayropharm
Looks like Geron is making a name for itself in the Hematological space already...... pre-approval and pre-commercialization.
Pretty exciting stuff I'd say. -Kmall
Platinum: Gilead & Novartis
Gold: Bristol Meyers Squibb
Silver: Syros
Bronze: Geron & Kayropharm
Looks like Geron is making a name for itself in the Hematological space already...... pre-approval and pre-commercialization.
Pretty exciting stuff I'd say. -Kmall
-
- Posts: 128
- Joined: Thu Jun 18, 2020 5:48 pm
Re: Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
What was the part about "not many patients enrolled yet" in the QT part (extension) of the study?
Do we know if that part has been fully enrolled yet?
Do we know if that part has been fully enrolled yet?
-
- Posts: 1665
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
HI not sure that timeline matters too much. TLR could still be released as planned while QT study still being completed. Pts probably have to get ECGS every hour around the clock for some period so it’s cumbersome. The QT interval is a direct measurement off the cardio gram and should be straightforward to obtain.
-
- Posts: 1665
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Imetelstat and HIF inhibitors evolving use in MDS Valeria Santini
Kmall, good points. Considering there are about 18,000 members of the Society, a substantial number including those from around the world will be attending the meetings. Sponsorship not only gets the name and information out but I imagine a prominent “booth” with information and personnel present to talk directly to care givers will be in evidence. They are turning up the heat.